NCT00804622 - Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

March 31, 2010

Conditions

Chronic Hepatitis B

Interventions

DRUG

telbivudine

daily oral administration,600mg,over 12 weeks

DRUG

tenofovir disproxil fumarate

daily oral administration,300mg,over 12 weeks

DRUG

telbivudine plus tenofovir disproxil fumarate

daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks

Trial Locations (1)

Department of Medicine, Queen Mary Hospital, Hong Kong